Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Nave Adult Patients with Metastatic Uveal Melanoma

Disease Sites: Not Available

Phase: II/III

Investigator: Johnson, Douglas

NCTID: NCT06581406

Protocol No: VICC-DTMEL24090

Clinical Trial Flowcharts
for Referring Physicians

Clinical Trial Flowcharts
for VICC Staff (VUNetID required)

Clinical Trials Search CTA Inline Referral Form